Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 26NETWORK 7INDUSTRY 4OTHER_GOV 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 15CNS 10Gastrointestinal 8Thoracic 6Genitourinary 4Dermatologic 3Head & Neck 2Tumor-Agnostic 1NET 1Gynecologic 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Surgical Procedures, Operative × Genitourinary × Clear all
NCT03924856 2026-05-28

KEYNOTE-866

Merck Sharp & Dohme LLC

Phase 3 Completed
907 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Merck Sharp & Dohme LLC

Phase 3 Completed
808 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT06305767 2026-01-13

INTerpath-005

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
230 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
595 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡